DOSE ADJUSTMENT PRACTICES OF PEGINESATIDE VS. EPOETIN IN EMERALD 1 AND 2 PIVOTAL TRIALS

• Ngā kaituhi matua: Amit Sharma (Author), Whedy Wang (Author), Alex Yang (Author), Ali Hariri (Author), Hong-Ye Gao (Author), Anne-Marie Duliege (Author), Krishna Polu (Author), Nina Oestreicher (Author)
• Hōputu: Pukapuka
• I whakaputaina: The Korean Society of Nephrology, 2012-06-01T00:00:00Z.
• Ngā marau: article
• Urunga tuihono: Connect to this object online.

Peginesatide (P) is a synthetic, pegylated, peptide-based ESA approved for treatment of anemia due to chronic kidney disease in adult patients (pts) on dialysis. P demonstrated noninferiority to epoetin (E) in maintenance of Hb levels in hemodialysis (HD) pts in two Phase 3 randomized, active-contro...